Solid Biosciences Inc. [NASDAQ: SLDB] price plunged by -1.23 percent to reach at -$0.05. The company report on June 7, 2021 that Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer.
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), announced the grant of an inducement award to its newly appointed Chief Regulatory Officer, Dr. Iman Barilero. The grant was approved by a majority of the independent directors of the Company on May 5, 2021 as an inducement material to Dr. Barilero entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The inducement grant to Dr. Barilero consisted of an option to purchase up to 180,000 shares of common stock. The option has an exercise price of $3.75 per share, the closing price per share of Solid Biosciences’ common stock as reported by Nasdaq on June 1, 2021. The option has a ten-year term and vests in four equal installments on each one-year anniversary of Dr. Barilero’s employment start date until the fourth anniversary of Dr. Barilero’s start date, subject to Dr. Barilero’s continued service with the Company through the applicable vesting dates.
A sum of 4770635 shares traded at recent session while its average daily volume was at 1.45M shares. Solid Biosciences Inc. shares reached a high of $4.915 and dropped to a low of $4.01 until finishing in the latest session at $4.01.
Guru’s Opinion on Solid Biosciences Inc. [SLDB]:
Jefferies have made an estimate for Solid Biosciences Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2021. While these analysts kept the previous recommendation, SVB Leerink dropped their target price from $3 to $15. The new note on the price target was released on March 16, 2021, representing the official price target for Solid Biosciences Inc. stock. Previously, the target price had yet another raise to $13, while Barclays analysts kept a Overweight rating on SLDB stock. On January 08, 2021, analysts increased their price target for SLDB shares from 2 to 7.
The Average True Range (ATR) for Solid Biosciences Inc. is set at 0.31, with the Price to Sales ratio for SLDB stock in the period of the last 12 months amounting to 136.25. The Price to Book ratio for the last quarter was 1.42.
SLDB Stock Performance Analysis:
Solid Biosciences Inc. [SLDB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.26. With this latest performance, SLDB shares dropped by -13.20% in over the last four-week period, additionally plugging by 14.25% over the last 6 months – not to mention a rise of 23.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SLDB stock in for the last two-week period is set at 45.81, with the RSI for the last a single of trading hit 53.14, and the three-weeks RSI is set at 42.84 for Solid Biosciences Inc. [SLDB]. The present Moving Average for the last 50 days of trading for this stock 4.59, while it was recorded at 3.85 for the last single week of trading, and 5.00 for the last 200 days.
Insight into Solid Biosciences Inc. Fundamentals:
Return on Total Capital for SLDB is now -77.08, given the latest momentum, and Return on Invested Capital for the company is -80.18. Return on Equity for this stock declined to -83.24, with Return on Assets sitting at -64.30. When it comes to the capital structure of this company, Solid Biosciences Inc. [SLDB] has a Total Debt to Total Equity ratio set at 3.90. Additionally, SLDB Total Debt to Total Capital is recorded at 3.75, with Total Debt to Total Assets ending up at 3.01. Long-Term Debt to Equity for the company is recorded at 2.23, with the Long-Term Debt to Total Capital now at 2.15.
Reflecting on the efficiency of the workforce at the company, Solid Biosciences Inc. [SLDB] managed to generate an average of -$1,261,286 per employee.Solid Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 12.00 and a Current Ratio set at 12.00.
SLDB Stock EPS
With the latest financial reports released by the company, Solid Biosciences Inc. posted -0.39/share EPS, while the average EPS was predicted by analysts to be reported at -0.5/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 22.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SLDB.
Solid Biosciences Inc. [SLDB] Insider Position Details
There are presently around $317 million, or 72.10% of SLDB stock, in the hands of institutional investors. The top three institutional holders of SLDB stocks are: PERCEPTIVE ADVISORS LLC with ownership of 13,412,552, which is approximately 24.146% of the company’s market cap and around 5.70% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 12,367,873 shares of the stock with an approximate value of $49.59 million in SLDB stocks shares; and ECOR1 CAPITAL, LLC, currently with $36.9 million in SLDB stock with ownership of nearly 15.355% of the company’s market capitalization.
Positions in Solid Biosciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 72 institutional holders increased their position in Solid Biosciences Inc. [NASDAQ:SLDB] by around 27,358,530 shares. Additionally, 32 investors decreased positions by around 2,831,208 shares, while 11 investors held positions by with 48,942,368 shares. The mentioned changes placed institutional holdings at 79,132,106 shares, according to the latest SEC report filing. SLDB stock had 40 new institutional investments in for a total of 11,860,413 shares, while 11 institutional investors sold positions of 634,885 shares during the same period.